Clicky

Eli Lilly and Company(LLY) News

Date Title
Jul 26 Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
Jul 26 Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
Jul 25 Biotech Is Booming, and This Undervalued REIT Stands to Gain
Jul 25 Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
Jul 25 Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Jul 25 Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Jul 25 In reversal, European regulators take positive view on Lilly Alzheimer’s drug
Jul 25 Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
Jul 24 Eli Lilly (LLY) Collaborates With Gate Bioscience For Innovative Molecular Gate Therapeutics
Jul 24 The 3 Things That Matter for Eli Lilly Now
Jul 24 This Weight-Loss Stock Sank After Earnings. It’s Still a Risk for Eli Lilly, Novo Nordisk.
Jul 24 How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
Jul 24 Lilly confirms date and conference call for second-quarter 2025 financial results announcement
Jul 24 Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
Jul 24 Selective Estrogen Receptor Degrader (SERDs) Market Research Report 2025-2030 Featuring AstraZeneca, Eli Lilly, EnhancedBio, Olema Oncology, Radius Therapeutics, and Roche
Jul 24 West Pharma soars on profit forecast raise, lowered tariff impact estimate
Jul 24 Lilly and Verve announce expiration of Verve tender offer
Jul 24 Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Jul 24 Benign Breast Disease and Early Breast Cancer Market Analysis Report 2025-2035 | Key Emerging Trends That are Reshaping the Landscape of Diagnosis, Treatment, and Patient Care
Jul 23 Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results